Crossmark

A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent

Crossref DOI link: https://doi.org/10.1007/s00280-017-3375-9

Published Online: 2017-07-12

Published Print: 2017-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fountzilas, Christos

Chhatrala, Ravi

Khushalani, Nikhil

Tan, Wei

LeVea, Charles

Hutson, Alan

Tucker, Chris

Ma, Wen Wee

Warren, Graham

Boland, Patrick

Iyer, Renuka
Funding

Funding for this research was provided by:

OSI Pharmaceuticals.
License Information

License valid from 2017-07-12